Lifeward Ltd. (LFWD) Study Shows Sustained, Safe ReWalk Home Use
Less than 1 min read
An independent, peer-reviewed study found ReWalk Personal Exoskeleton users with chronic paraplegia maintained long-term home use (median 33 months) with no reported falls or device-related fractures and 3,000+ steps per month, supporting broader access and reimbursement.
Material Details
| # | Detail | AI Analyst View |
|---|---|---|
| 1 | Median use 33 months at home | Long-term adherence supports durability and real-world value, aiding payer and clinician adoption. |
| 2 | No reported falls or fractures | Positive safety profile reduces perceived risk, important for reimbursement and prescriptions. |
| 3 | 3,000+ steps per month sustained | Demonstrates ongoing utilization, countering concerns about drop-off after training. |
| 4 | High user satisfaction reported | Quality-of-life gains can influence payer coverage and patient demand. |
| 5 | Medicare coverage noted | Existing CMS coverage plus new data may expand access and sales. |
| 6 | Independent, peer-reviewed study | Third-party validation strengthens evidence base for market adoption. |
Context by AI Analyst
This is incremental but supportive evidence extending prior short-term data into multi-year real-world use. A larger, multi-center dataset with economic outcomes and payer policy updates would turn this into a stronger commercial catalyst.
Based on the original press release from Lifeward Ltd. distributed by GlobeNewswire.
This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by GlobeNewswire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.